Last reviewed · How we verify

Sedative analgesia/muscle relaxant therapy

Second Affiliated Hospital, School of Medicine, Zhejiang University · FDA-approved active Small molecule

Sedative analgesia/muscle relaxant therapy combines central nervous system depressants and analgesics to produce sedation, pain relief, and muscle relaxation for clinical use.

Sedative analgesia/muscle relaxant therapy combines central nervous system depressants and analgesics to produce sedation, pain relief, and muscle relaxation for clinical use. Used for Perioperative sedation and analgesia, Intensive care unit sedation and analgesia, Procedural sedation with muscle relaxation.

At a glance

Generic nameSedative analgesia/muscle relaxant therapy
Also known asPropofol, midazolam, dexmedetomidine
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
ModalitySmall molecule
Therapeutic areaAnesthesia/Critical Care
PhaseFDA-approved

Mechanism of action

This is a therapeutic approach rather than a single drug entity, typically combining sedatives (such as benzodiazepines or propofol), opioid analgesics, and muscle relaxants (such as neuromuscular blocking agents) to achieve simultaneous sedation, analgesia, and skeletal muscle relaxation. The combination allows for reduced dosing of individual agents while achieving the desired clinical endpoints in perioperative or critical care settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: